Recro Pharma Inc (NASDAQ:REPH) major shareholder Stonepine Capital Management, sold 217,308 shares of the stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $7.70, for a total transaction of $1,673,271.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Stonepine Capital Management, also recently made the following trade(s):
- On Friday, May 12th, Stonepine Capital Management, sold 510,000 shares of Recro Pharma stock. The stock was sold at an average price of $7.40, for a total transaction of $3,774,000.00.
- On Thursday, May 11th, Stonepine Capital Management, sold 244,629 shares of Recro Pharma stock. The stock was sold at an average price of $7.65, for a total transaction of $1,871,411.85.
Recro Pharma Inc (NASDAQ:REPH) traded down 1.19% on Friday, hitting $8.29. 16,457 shares of the company were exchanged. The stock’s 50-day moving average price is $8.03 and its 200-day moving average price is $7.74. Recro Pharma Inc has a 52-week low of $5.89 and a 52-week high of $12.50. The stock’s market capitalization is $157.92 million.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.15. Recro Pharma had a negative return on equity of 57.17% and a negative net margin of 13.34%. The firm had revenue of $18.74 million during the quarter, compared to the consensus estimate of $15.58 million. On average, equities research analysts anticipate that Recro Pharma Inc will post ($2.39) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Insider Selling: Recro Pharma Inc (REPH) Major Shareholder Sells 217,308 Shares of Stock” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/05/19/stonepine-capital-management-sells-217308-shares-of-recro-pharma-inc-reph-stock-updated.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Broadfin Capital LLC increased its position in Recro Pharma by 26.5% in the fourth quarter. Broadfin Capital LLC now owns 3,100,086 shares of the specialty pharmaceutical company’s stock valued at $24,987,000 after buying an additional 650,000 shares in the last quarter. Stonepine Capital Management LLC increased its stake in shares of Recro Pharma by 145.5% in the fourth quarter. Stonepine Capital Management LLC now owns 2,874,317 shares of the specialty pharmaceutical company’s stock worth $23,167,000 after buying an additional 1,703,717 shares during the period. Deerfield Management Co. bought a new stake in shares of Recro Pharma during the fourth quarter worth about $16,725,000. Alyeska Investment Group L.P. increased its stake in shares of Recro Pharma by 1,571.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 862,761 shares of the specialty pharmaceutical company’s stock worth $6,954,000 after buying an additional 811,142 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Recro Pharma by 44.4% in the first quarter. Vanguard Group Inc. now owns 560,688 shares of the specialty pharmaceutical company’s stock worth $4,901,000 after buying an additional 172,492 shares during the period. 53.23% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have commented on the stock. Roth Capital set a $20.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Saturday, May 13th. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 target price on the stock in a research note on Wednesday. Finally, Aegis restated a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research note on Monday, March 27th. Seven analysts have rated the stock with a buy rating, Recro Pharma has a consensus rating of “Buy” and a consensus price target of $16.21.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.